26 Jun 2019

ABBVIE ACQUIRING ALLERGAN AS HEDGE AGAINST EXPIRATION OF HUMIRA PATENT

As a hedge against the 2023 expiration of its U.S. patents that protect its blockbuster drug, Humira, AbbVie Inc. will acquire Dublin, Ireland-based Allergan for $63 billion in cash and stock.     Humira sales account for more than 60 percent of AbbVie’s revenue, but biosimilar drugs approved in Europe

0
25 Jun 2019

RATIONAL SUICIDE: Seniors want to call it quits on own schedule

(Caitlin Hillyard/KHN) By Melissa Bailey Ten residents slipped away from their retirement community one Sunday afternoon for a covert meeting in a grocery store cafe. They aimed to answer a taboo question: When they feel they have lived long enough, how can they carry out their own swift and peaceful

0
19 Jun 2019

VSA, PRACTICE MANAGEMENT FIRM, OBSERVES 17TH YEAR

  Vein Centers of America (VSA) is celebrating its 17th anniversary by offering a complimentary phone consultation with President and CEO David Schmiege.              in vein-specific practice management, marketing and revenue cycle management initiatives nationwide. “We have the experience, flexibility, structure and size to implement results quickly and to create the culture

0
13 Jun 2019

DO YOUR OLDER PATIENTS REGARD THEIR HEALTH AS GOOD OR POOR?

    By Judith Graham A common myth about aging is that older adults are burdened by illness and feel lousy much of the time. In fact, the opposite is usually true. Most seniors report feeling distinctly positive about their health. Consider data from the 2017 National Health Interview Survey (the most

0
12 Jun 2019

VICI VENOUS STENT: FDA OKs VICI Venous Stent to treat Iliofemoral obstructive disease

    The U.S Food and Drug Administration has approved Boston Scientific’s VICI Venous Stent System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked by a blood clot or compressed by anatomical anomalies.

0
12 Jun 2019

VECLOSE EXTENSION STUDY: Five-year outcomes prove durability, safety, efficacy of VenaSeal Closure System

    By Larry Storer Five-year results from the 2019 VeClose Extension Study of the Medtronic VenaSeal Closure System demonstrate that the treatment modality is consistent, durable and safe for permanently closing veins in patients with venous reflux disease. When compared with Medtronic Radiofrequency Ablation, VenaSeal continued to show “non-inferiority”

0
12 Jun 2019

MERZ REGAINS SOLE DISTRIBUTION OF ASCLERA FROM ANGIODYNAMICS

  Merz North America Inc. has regained exclusive distribution of Asclera (polidocanol) Injection in the United States to all healthcare practitioners and phlebologists treating varicose veins. Also effective April 8, AngioDynamics Inc. is no longer an authorized distributor of Asclera. All HCPs will now be able to purchase Asclera directly

0
12 Jun 2019

NEVER SAY DIE: WHY MOST DOCTORS WON’T BREAK BAD NEWS

  By JoNel Aleccia After nearly 40 years as an internist, Portland, Oregon physician Ron Naito knew what the sky-high results of his blood test meant. And it wasn’t good. But when he turned to his doctors last summer to confirm the dire diagnosis — stage 4 pancreatic cancer —

0
11 Jun 2019

WHEN IT COMES TO OUR HEALTH – EVERY SECOND COUNTS

By Seema Verma Healthcare: American’s favorite debate topic.  While there is much to debate, we can all agree that the patient-provider relationship has been strained by unnecessary regulations and reporting requirements. Too much regulation has had the unintentional result of putting the government first and the patient second.  Time spent

0
10 Jun 2019

AVLS offers sclerotherapy and hands-on ultrasound courses Aug. 10

            Margaret Mann, MD, FACPh, will conduct the American Vein and Lymphatic Society Sclerotherapy Course Aug. 10 in Arlington, Va.             The Sclerotherapy Course is a comprehensive one-day lecture series, reviewing both the theoretical and practical essentials of sclerotherapy. This course will enhance your sclerotherapy knowledge

0